Welcome to our dedicated page for Rapt Therapeutics news (Ticker: RAPT), a resource for investors and traders seeking the latest updates and insights on Rapt Therapeutics stock.
RAPT Therapeutics, Inc. news centered on clinical-stage immunology drug development for inflammatory and immunological diseases, including ozureprubart, formerly RPT904, an anti-IgE therapy evaluated in IgE-mediated food allergy and chronic spontaneous urticaria. Company updates covered clinical trial initiation and data releases, collaboration-related development with Shanghai Jeyou Pharmaceutical, financial results, public equity financing, and investor conference presentations.
The company's public-company history also includes a completed merger in which RAPT became a wholly owned subsidiary of GlaxoSmithKline LLC, followed by Nasdaq delisting and Exchange Act deregistration filings. Corporate updates provide historical context for its former Nasdaq-listed common stock and immunology pipeline disclosures.
RAPT Therapeutics, Inc. (Nasdaq: RAPT) reported Q1 2022 financial results, revealing a net loss of $20.5 million, up from $16.5 million in Q1 2021. Research and development expenses increased to $16.7 million due to clinical trial costs for RPT193 and FLX475. General and administrative expenses rose to $4.7 million. The company is advancing its clinical trials, including initiating a Phase 2b trial for RPT193 in atopic dermatitis and a Phase 2a trial for asthma. RAPT maintains a solid cash position of $173.0 million.
RAPT Therapeutics, Inc. (Nasdaq: RAPT) recently announced key leadership appointments, including Gwen Carscadden as Chief Human Resources Officer, Jim Farmer as Vice President of Clinical Operations, and Shari Geffon as Vice President of Program and Alliance Management. These hires are seen as pivotal in advancing RPT193 and FLX475 through clinical development. The company aims to address significant unmet needs in inflammatory diseases and oncology, leveraging the extensive experience of these new executives in their respective fields.
RAPT Therapeutics has reported promising biomarker data from its Phase 1b trial of RPT193 for moderate-to-severe atopic dermatitis, presented at the American Academy of Dermatology Annual Meeting. Key findings indicate a statistically significant improvement in the meta-analysis derived atopic dermatitis (MADAD) score (p<0.001) and positive changes in immune pathways linked to the disease. RAPT aims to initiate a Phase 2b clinical trial in atopic dermatitis, with plans to expand RPT193's development into asthma.
RAPT Therapeutics, Inc. reported its financial results for Q4 2021 and the full year, highlighting a net loss of $17.9 million for Q4 and $69.2 million for the year, an increase from $12.7 million and $52.9 million in 2020, respectively. R&D expenses rose to $14.3 million in Q4 and $57.0 million for the year due to clinical trial costs for RPT193 and FLX475. General and administrative expenses also increased to $4.5 million in Q4 and $16.0 million for the year. The company maintained a robust cash position of $189.7 million as of year-end.
SOUTH SAN FRANCISCO, Calif., Feb. 09, 2022 – RAPT Therapeutics, a clinical-stage biopharmaceutical company, announced that Brian Wong, M.D., Ph.D., President and CEO, will participate in a virtual fireside chat at the 11th Annual SVB Leerink Healthcare Conference on February 16, 2022, at 1:40 p.m. ET. The event will discuss the company's focus on developing oral small molecule therapies for inflammatory diseases and oncology. Interested parties can access the live or archived webcast on the RAPT Therapeutics website.
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 – RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage biopharmaceutical company, announced that President and CEO Brian Wong, M.D., Ph.D., will present at the 40th Annual J.P. Morgan Healthcare Conference. The event will take place on January 11, 2022, at 9:00 a.m. ET. RAPT focuses on developing oral small molecule therapies for inflammatory diseases and oncology. The company has advanced drug candidates RPT193 and FLX475, targeting CCR4 for treating inflammation and cancer. Access the presentation via the RAPT website.
RAPT Therapeutics reported a net loss of $18.7 million for Q3 2021, up from $14.6 million in Q3 2020. Research and development expenses rose to $15.7 million due to clinical trial costs for FLX475 and RPT193. Total net loss for the nine months ended September 30, 2021, was $51.3 million, compared to $40.2 million in the prior year. RAPT aims to advance RPT193 into Phase 2 trials in 2022 and is focusing on FLX475 for various cancers, with data updates expected at a medical meeting in 2022. The company holds $210.8 million in cash and securities.
RAPT Therapeutics, a clinical-stage biopharmaceutical company, has appointed Lori Lyons-Williams to its Board of Directors. With over 20 years of experience, she previously held key roles at Neumora Therapeutics and Dermira, driving strategic success in biotechnology. Her expertise is expected to significantly benefit RAPT's inflammation and oncology product pipeline, particularly RPT193. RAPT develops oral small molecule therapies for patients with severe unmet needs, focusing on inflammatory diseases and cancer.
RAPT Therapeutics, based in South San Francisco, announced that CEO Brian Wong will present at key investor conferences in November 2021. These include the Stifel 2021 Virtual Healthcare Conference on November 15 at 2:00 p.m. ET and the Piper Sandler 33rd Annual Virtual Healthcare Conference on November 22 available on-demand at 10:00 a.m. ET. RAPT Therapeutics focuses on developing oral small molecule therapies for inflammatory diseases and oncology, with drug candidates like RPT193 and FLX475 targeting CCR4.
RAPT Therapeutics, Inc. (Nasdaq: RAPT) announced the presentation of clinical efficacy data from its Phase 1b trial of RPT193, an oral CCR4 inhibitor for moderate-to-severe atopic dermatitis. The presentation will occur at the 4th Inflammatory Skin Disease Summit in New York, from November 3-6, 2021. The trial is designed to demonstrate the efficacy of RPT193 compared to a placebo. This is part of RAPT's commitment to developing therapies for significant unmet needs in oncology and inflammatory diseases.